Smith Shellnut Wilson LLC ADV Has $264,000 Stock Position in Pfizer Inc. (NYSE:PFE)

Smith Shellnut Wilson LLC ADV lessened its position in Pfizer Inc. (NYSE:PFE) by 39.0% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,449 shares of the biopharmaceutical company’s stock after selling 6,032 shares during the period. Smith Shellnut Wilson LLC ADV’s holdings in Pfizer were worth $264,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of PFE. Olistico Wealth LLC acquired a new position in shares of Pfizer during the second quarter valued at about $25,000. MFA Wealth Advisors LLC bought a new stake in shares of Pfizer in the 2nd quarter worth approximately $29,000. Creekmur Asset Management LLC purchased a new stake in shares of Pfizer during the 4th quarter valued at approximately $32,000. Trivant Custom Portfolio Group LLC boosted its position in shares of Pfizer by 100.0% in the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 600 shares during the period. Finally, DiNuzzo Private Wealth Inc. purchased a new stake in shares of Pfizer in the 4th quarter valued at about $37,000. Institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on PFE shares. Wells Fargo & Company boosted their target price on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. StockNews.com raised Pfizer from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. BMO Capital Markets reiterated an “outperform” rating and set a $36.00 price objective (up previously from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a report on Monday, August 19th. Eight analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $34.54.

Pfizer Stock Down 0.3 %

Shares of Pfizer stock traded down $0.09 during trading hours on Tuesday, hitting $28.84. 16,156,843 shares of the company’s stock traded hands, compared to its average volume of 38,734,188. The stock has a 50 day simple moving average of $28.89 and a 200-day simple moving average of $27.98. The company has a market cap of $163.40 billion, a PE ratio of -480.33, a PEG ratio of 0.98 and a beta of 0.69. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $36.94. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The business had revenue of $13.28 billion for the quarter, compared to analyst estimates of $12.96 billion. During the same quarter last year, the business earned $0.67 earnings per share. The business’s revenue for the quarter was up 2.1% on a year-over-year basis. Equities research analysts anticipate that Pfizer Inc. will post 2.68 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th will be given a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 5.83%. The ex-dividend date of this dividend is Friday, July 26th. Pfizer’s dividend payout ratio is currently -2,800.00%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.